
ARCA biopharma ABIO
Quartalsbericht 2025-Q3
hinzugefügt 12.11.2025
ARCA biopharma EV 2011-2026 | ABIO
EV Jährlich ARCA biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 436 M | -13.8 M | -11.1 M | -23.2 M | -19.8 M | -474 K | 279 K | 12.2 M | 18.2 M | -13.5 M | 593 K | 2.01 M | 6.46 M | 4.76 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 436 M | -23.2 M | 28.5 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
82.6 M | $ 8.7 | 8.82 % | $ 86 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.63 | -2.42 % | $ 8.73 B | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
197 M | $ 3.06 | 3.73 % | $ 261 M | ||
|
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | ||
|
BioNTech SE
BNTX
|
-4.91 B | $ 97.5 | 2.09 % | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 20.5 | 0.64 % | $ 958 M | ||
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
493 M | $ 1.43 | 1.79 % | $ 368 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 2.96 | 1.37 % | $ 4.87 M | ||
|
Aquestive Therapeutics
AQST
|
540 M | $ 4.16 | 1.84 % | $ 445 M | ||
|
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | ||
|
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 24.22 | 0.04 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
2.07 B | $ 32.51 | 0.84 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.51 | 1.01 % | $ 402 M | ||
|
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
9.99 M | - | - | $ 1.41 B | ||
|
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-15.2 M | $ 2.61 | 2.35 % | $ 16.4 M | ||
|
InflaRx N.V.
IFRX
|
-2.36 M | $ 1.07 | 7.0 % | $ 152 M | ||
|
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
Akari Therapeutics, Plc
AKTX
|
79.3 B | $ 3.99 | 4.2 % | $ 269 B | ||
|
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | ||
|
Baudax Bio
BXRX
|
29.8 M | - | 0.59 % | $ 63 K | ||
|
Cabaletta Bio
CABA
|
253 M | $ 3.25 | 3.83 % | $ 327 M | ||
|
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B |